Key regions: South Korea, India, China, Australia, Italy
Papua New Guinea, the largest country in the Pacific region, is home to a diverse population with over 800 languages spoken. While the country has made significant progress in reducing infant mortality rates, access to healthcare remains a challenge in many parts of the country. The Vaccines market in Papua New Guinea is developing slowly due to various factors.
Customer preferences: There is a growing awareness among the population about the importance of vaccines in preventing diseases. However, traditional beliefs and practices continue to influence customer preferences in some parts of the country. Additionally, the high cost of vaccines and the lack of access to healthcare facilities are major barriers to the adoption of vaccines in the country.
Trends in the market: The Vaccines market in Papua New Guinea is witnessing a slow but steady growth due to the increasing government focus on improving healthcare infrastructure. The government has launched several initiatives to increase vaccination coverage in the country, especially in rural areas. The private sector is also playing a significant role in expanding the availability of vaccines in the country.
Local special circumstances: Papua New Guinea has a challenging geography with many remote and inaccessible areas, making it difficult to deliver vaccines to all parts of the country. The country also faces several health challenges, including a high burden of infectious diseases such as tuberculosis, malaria, and HIV/AIDS. These factors have a significant impact on the demand for vaccines in the country.
Underlying macroeconomic factors: Papua New Guinea's economy is heavily dependent on natural resources, with mining and agriculture being the major contributors to the country's GDP. The country has been facing economic challenges in recent years due to the decline in commodity prices and the impact of the COVID-19 pandemic. These factors have a significant impact on the government's ability to invest in healthcare infrastructure and vaccine programs.In conclusion, the Vaccines market in Papua New Guinea is slowly developing due to the challenges posed by the country's geography, traditional beliefs, and economic situation. However, the increasing focus on healthcare infrastructure and the role of the private sector are expected to drive growth in the market in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
